Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRD induction therapy in newly diagnosed multiple myeloma
ChiCTR1900022551Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: Overall response rate. Planned start May 2019; status: not yet recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900022551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022551.